Chronic obstructive pulmonary disease (COPD)

Drugs of the Future

Volumn 32, Issue 9, 2007, Pages 799-807

  Pahl, Andreas ^a   Szelenyi, Istvan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; ABN 912; AWD 12281; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; I KAPPA B; INFLIXIMAB; IPRATROPIUM BROMIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXITROPIUM BROMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROTEINASE INHIBITOR; REVATROPATE; ROLIPRAM; SALMETEROL; SB 265610; SB 332235; SB 656933; SB 681323; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARDAVERINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED DRUG RELEASE; CROSS REACTION; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; EMPHYSEMA; HUMAN; NAUSEA; NONHUMAN; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 36348981627     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.09.1126938     Document Type: Review

References (61)

1. D'Souza, A.O., Smith, M.J., Miller, L.A., Kavookjian, J. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 2006, 129(6): 1693-708.
2. Gross, N.J., Co, E., Skorodin, M.S. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989, 96(5): 984-7.
3. Gosens, R., Zaagsma, J., Meurs, H., Halayko, A.J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006, 7: 73.
4. Anzueto, A., Tashkin, D., Menjoge, S., Kesten, S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005, 18(2): 75-81.
5. Schelfhout, V.J., Joos, G.F., Ferrer, P., Luria, X., Pauwels, R.A. Activity of LAS 34273, a new long acting anticholinergic antagonist. Am J Respir Crit Care Med 2003, 167: A93.
6. Alabaster, V.A. Discovery & development of selective M3 antagonists for clinical use. Life Sci 1997, 60(13-14): 1053-60.
7. Villetti, G., Bergamaschi, M., Bassani, F. et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol 2006, 148(3): 291-8.
8. Profita, M., Giorgi, R.D., Sala, A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005, 60(11): 1361-9.
9. Pahl, A., Bauhofer, A., Petzold, U. et al. Synergistic effects of the anti-cholinergic R,R-glycopyrrolate with anti-inflammatory drugs. Biochem Pharmacol 2006, 72(12): 1690-6.
10. Sin, D.D., Man, S.F., Marciniuk, D.D. et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulm Med 2006, 6: 3.
11. Buhl, R., Farmer, S.G. Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2(1): 83-93.
12. Nichols, J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy 2007, 27(3): 447-54.
13. Richter, K., Stenglein, S., Mucke, M. et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006, 73(4): 414-9.
14. van Noord, J.A., Aumann, J.L., Janssens, E. et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129(3): 509-17.
15. Calverley, P.M. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004, 1(2): 121-4.
16. O'Donnell, D.E., Sciurba, F., Celli, B. et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006, 130(3): 647-56.
17. Mapel, D.W., Nelson, L.S., Lydick, E., Soriano, J., Yood, M.U., Davis, K.J. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 2007, 4(2): 127-34.
18. Aaron, S.D., Vandemheen, K.L., Fergusson, D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007, 146(8): 545-55.
19. Lipworth, B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365(9454): 167-75.
20. Rabe, K.F., Bateman, E.D., O'Donnell, D., Witte, S., Bredenbroker, D., Bethke, T.D. Roflumilast - An oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2005, 366(9485): 563-71.
21. Kuss, H., Hoefgen, N., Johanssen, S., Kronbach, T., Rundfeldt, C. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4- fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307(1): 373-85.
22. Brunnee, T., Engelstatter, R., Steinijans, V.W., Kunkel, G. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 1992, 5(8): 982-5.
23. Sun, B., Li, H., Shakur, Y. et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 2007, 19(8): 1765-71.
24. 2+stimulated exocytosis of insulin. Cell Signal 2007, 19(7): 1505-13.
25. Edmondson, S.D., Mastracchio, A., He, J. et al. Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg Med Chem Lett 2003, 13(22): 3983-7.
26. Mukhopadhyay, S., Hoidal, J.R., Mukherjee, T.K. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006, 7: 125.
27. Churg, A., Dai, J., Tai, H., Xie, C., Wright, J.L. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002, 166(6): 849-54.
28. van der Vaart, H., Koeter, G.H., Postma, D.S., Kauffman, H.F., ten Hacken, N.H. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172(4): 465-9.
29. Rennard, S.I., Fogarty, C., Kelsen, S. et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9): 926-34.
30. Hogg, J.C., Chu, F., Utokaparch, S. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. New Eng J Med 2004, 350(26): 2645-53.
31. Chung, K.F. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 2001, 34: 50s-9s.
32. Bozinovski, S., Jones, J., Beavitt, S.J., Cook, A.D., Hamilton, J.A., Anderson, G.P. Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am J Physiol Lung Cell Mol Physiol 2004, 286(4): L877-85.
33. Puljic, R., Benediktus, E., Plater-Zyberk, C. et al. Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol 2007, 557(2-3): 230-5.
34. Vlahos, R., Bozinovski, S., Hamilton, J.A., Anderson, G.P. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther 2006, 112(1): 106-15.
35. de Boer, W.I., Sont, J.K., van Schadewijk, A., Stolk, J., van Krieken, J.H., Hiemstra, P.S. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000, 190(5): 619-26.
36. Traves, S.L., Culpitt, S.V., Russell, R.E., Barnes, P.J., Donnelly, L.E. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57(7): 590-5.
37. Fitzgerald, M.F., Fox, J.C. Emerging trends in the therapy of COPD: Novel anti-inflammatory agents in clinical development. Drug Discov Today 2007, 12(11-12): 479-86.
38. Keatings, V.M., Collins, P.D., Scott, D.M., Barnes, P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153(2): 530-4.
39. Yang, X.D., Corvalan, J.R., Wang, P., Roy, C.M., Davis, C.G. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999, 66(3): 401-10.
40. Mahler, D.A., Huang, S., Tabrizi, M., Bell, G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study. Chest 2004, 126(3): 926-34.
41. Stevenson, C.S., Coote, K., Webster, R. et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005, 288(3): L514-22.
42. Thatcher, T.H., McHugh, N.A., Egan, R.W. et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005, 289(2): L322-8.
43. Belvisi, M.G., Bottomley, K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs? Inflamm Res 2003, 52(3): 95-100.
44. Schieven, G.L. The biology of p38 kinase: A central role in inflammation. Curr Top Med Chem 2005, 5(10): 921-8.
45. Zarubin, T., Han, J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005, 15(1): 11-8.
46. Peifer, C., Wagner, G., Laufer, S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem 2006, 6(2): 113-49.
47. Zhang, J., Shen, B., Lin, A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007, 28(6): 286-95.
48. Underwood, D.C., Osborn, R.R., Bochnowicz, S. et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000, 279(5): L895-902.
49. Haddad, E.B., Birred, M., McCluskie, K. et al. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 2001, 132(8): 1715-24.
50. Wetzker, R., Rommel, C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des 2004, 10(16): 1915-22.
51. Sasaki, T., Irie-Sasaki, J., Jones, R.G. et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000, 287(5455): 1040-6.
52. Rommel, C., Camps, M., Ji, H. PI3K delta and PI3K gamma: Partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007, 7(3): 191-201.
53. Di Stefano, A., Caramori, G., Oates, T. et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002, 20(3): 556-63.
54. Caramori, G., Romagnoli, M., Casolari, P. et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003, 58(4): 348-51.
55. Ghosh, S., Karin, M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl.): S81-96.
56. Adcock, I.M., Chung, K.F., Caramori, G., Ito, K. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006, 533(1-3): 118-32.
57. Strand, J., Burke, J.R. IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: Potential and challenges. Trends Pharmacol Sci 2007, 28(3): 142-8.
58. Birrell, M.A., Wong, S., Hardaker, E.L. et al. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: Relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006, 69(6): 1791-800.
59. Roth, M.D., Connett, J.E., D'Armiento, J.M. et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006, 130(5): 1334-45.
60. Kasahara, Y., Tuder, R.M., Taraseviciene-Stewart, L. et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000, 106(11): 1311-9.
61. Koyama, S., Sato, E., Haniuda, M., Numanami, H., Nagai, S., Izumi, T. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002, 166(3): 382-5.